Literature DB >> 17678433

An update on the management of Chagas cardiomyopathy.

Manoel O C Rocha1, Mauro M Teixeira, Antonio L Ribeiro.   

Abstract

Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, infects nearly 18 million people in Latin America and mainly affects the heart, causing heart failure, arrhythmias, heart block, thromboembolism, stroke and death. In this review, the clinical diagnosis and management of Chagas cardiomyopathy are discussed. Particular emphasis is placed on the clinical staging of patients and the use of various diagnostic tests that may be useful in individualizing treatment of the two most relevant clinical syndromes, that is, heart failure and arrhythmias. The relevance of specific treatments are discussed, stressing the important role of parasite persistence in disease pathogenesis. We also discuss new therapy modalities that may have a role in the treatment of Chagas cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17678433     DOI: 10.1586/14787210.5.4.727

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  48 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  New drugs for neglected infectious diseases: Chagas' disease.

Authors:  Fabiana S Machado; Herbert B Tanowitz; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

3.  Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

Authors:  S M Keating; X Deng; F Fernandes; E Cunha-Neto; A L Ribeiro; B Adesina; A I Beyer; P Contestable; B Custer; M P Busch; E C Sabino
Journal:  Int J Cardiol       Date:  2015-07-12       Impact factor: 4.164

4.  Enhanced parasympathetic activity in Chagas disease still stands in need of proof.

Authors:  Antonio Luiz P Ribeiro; Antonio Carlos Campos de Carvalho; Federico Lombardi; Mauro Martins Teixeira; Manoel Otávio Costa Rocha
Journal:  Int J Cardiol       Date:  2008-07-03       Impact factor: 4.164

Review 5.  Current concepts in immunoregulation and pathology of human Chagas disease.

Authors:  Walderez O Dutra; Kenneth J Gollob
Journal:  Curr Opin Infect Dis       Date:  2008-06       Impact factor: 4.915

6.  Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease.

Authors:  Walderez Ornelas Dutra; Cristiane Alves Silva Menezes; Fernanda Nobre Amaral Villani; Germano Carneiro da Costa; Alexandre Barcelos Morais da Silveira; Débora d'Avila Reis; Kenneth J Gollob
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

Review 7.  Parasitic infections and myositis.

Authors:  Samar N El-Beshbishi; Nairmen N Ahmed; Samar H Mostafa; Goman A El-Ganainy
Journal:  Parasitol Res       Date:  2011-09-01       Impact factor: 2.289

8.  In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi.

Authors:  Bruno Lisboa Timm; Patrícia Bernadino da Silva; Marcos Meuser Batista; Francisca Hildemagna Guedes da Silva; Cristiane França da Silva; Richard R Tidwell; Donald A Patrick; Susan Kilgore Jones; Stanislav A Bakunov; Svetlana M Bakunova; Maria de Nazaré C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 9.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

10.  In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi.

Authors:  Cristiane França da Silva; Marcos Meuser Batista; Denise da Gama Jaen Batista; Elen Mello de Souza; Patrícia Bernardino da Silva; Gabriel Melo de Oliveira; Andrea Souza Meuser; Abdur-Rafay Shareef; David W Boykin; Maria de Nazaré C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.